Suven Life SciencesQ3 FY20

Suven Life Sciences Q3 FY20 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹268.65Market Cap: ₹7.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Suven Pharma expects 15-20% growth in revenue for FY21 and beyond, based on expanded activities and capacities.
  • Growth outlook is driven by a mix of contract manufacturing, specialty chemicals, new ANDA filings, and commercial CRAMS.
  • The company acknowledges variability in quarter-to-quarter performance but maintains confidence in overall annual growth.
  • FROM FY21 onwards, growth is expected to improve further with new infrastructure and expanded activities.
  • The capacity utilization is effectively 100%, with a mix-and-match product approach allowing flexibility.
  • Long-term growth potential is positive, though exact segmental contributions are not disclosed.
  • Management emphasizes value over volume, focusing on high-margin products rather than sheer volume increases.
  • Growth guidance is based on past performance, project pipeline, and gut feeling but with uncertainty acknowledged.

See what Suven Life Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Suven Life Sciences plans to raise new sources of income within one year, potentially through monetization, strategic partners, or an IPO.
  • Management indicates the need for raising money within the next 12 months to continue activities; otherwise, funds may run out in 15-18 months.
  • No specific timeline or definite plans for new fundraising through debt or equity were disclosed, but several options (monetization, strategic investor, IPO) are under consideration.
  • Suven Pharma currently has working capital debt of about Rs. 32-35 crore and no long-term debt; no mention of immediate new debt raising.
  • Monetization opportunities for Suven Neurosciences through a US IPO are planned about 2.5 years from now.
  • Strategic investor interest is possible post-demerger, but no active search or commitment announced yet.

See what Suven Life Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Suven Pharma has a total planned CAPEX of Rs. 320 crore, with Rs. 160 crore already spent and the balance expected to be spent by the end of FY20 (Pages 5-6).
  • For FY21, only replacement CAPEX of Rs. 50 crore is planned; no major new CAPEX is planned currently (Page 6).
  • The Rs. 320 crore CAPEX spans specialty chemicals, intermediates, formulation, and niche API (backward integration for internal and CRAMS customers) but not large-scale API commercial production (Pages 11-15).
  • Capacity expansion is focused on reactor capacity (about 300 kiloliters), supporting a mix-and-match batch production model rather than fixed product capacity (Page 11).
  • Management bandwidth is planned to be expanded, with a senior executive (COO level) recruitment expected within 3-4 months to support CRAMS expansion (Page 4).
  • Strategic investors could be considered post-demerger in the CRAMS business, but no active search has started (Page 7).

Track Suven Life Sciences — get its next earnings analysis in your feed

How does Suven Life Sciences rank vs peers in Healthcare Services?

Pro feature
ThisSuven Life Sciences
Rev 3Mar 3

How does Suven Life Sciences rank in Healthcare Services?

Compare Suven Life Sciences against every Healthcare Services company (Q3 FY20) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →